L-165041
L-165041 性质
| 熔点 | 127-128 °C(lit.) |
|---|---|
| 沸点 | 600.8±55.0 °C(Predicted) |
| 密度 | 1.222±0.06 g/cm3(Predicted) |
| 储存条件 | 2-8°C |
| 溶解度 | 二甲基亚砜：>10 mg/mL |
| 形态 | 固体 |
| 酸度系数(pKa) | 3.23±0.10(Predicted) |
| 颜色 | 米白色 |
| 稳定性 | 感光 |
L-165041 用途与合成方法
|
PPARδ 6 nM (Ki) |
PPARγ 730 nM (Ki) |
L-165041 is a PPARδ agonist, with K i s of 6 nM and appr 730 nM for PPARδ and PPARγ, respectively. L-165041 (1 or 5 µM) inhibits VEGF-induced endothelial cells (ECs) proliferation and migration. L-165041 negatively affects cell cycle progression in VEGF-activated human umbilical vein ECs (HUVECs). L-165041 (10 µM)inhibits PPARδ-independent, VEGF-induced angiogenesis. PPARδ ligand L-165041 inhibits PDGF-induced rVSMC proliferation and migration. With 1 h of L-165041 pretreatment, PDGF-induced cellular migration is inhibited. L-165041 (10 μM) significantly suppresses S phase transition induced by PDGF.
L-165041 (5 mg/kg/day, i.p.) significantly lowers the formation of lipid droplets in mice. L-165041 markedly reduces the level of both the hepatic cholesterol and triglycerides in mice. L-165041 increases mRNA expression levels of PPARδ compared to the vehicle group. Lipoprotein lipase (LPL) expression in L-165041-treated mice is significantly higher than that in the vehicle group.
L-165041 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-11-08 | HY-20019 | L-165041 | 79558-09-1 | 5mg | 500 |
| 2024-11-08 | HY-20019 | L-165041 | 79558-09-1 | 10mM * 1mLin DMSO | 550 |
